We revisit epilepsy needs in the United Kingdom, and update our previous publication to take into account new epidemiological data, changes in investigation and treatment and trends in the organization of health and other caring ageneies. This document attempts to define and quantify the scope, content and standards of services required, from primary care settings to specialized centres. Reference is also made to the role of other agencies.
INTRODUCTION
At the end of the first epilepsy needs document ('Needs I ') in 1993', we noted the opportunity for epilepsy to move further up the health service agenda and concluded with a commitment to review the paper in 5 years time. Now that 5 years have elapsed, we take stock of some changes and revisit epilepsy needs in the UK.
Needs 1 has run to some 20 000 reprints, and has been cited in many other publications. Out of it there arose an initiative called the Epilepsy Task Force** which in turn has produced documentation to assist health managers and planners in developing epilepsy services'.3, using Needs I as its basis. The Task Force Specification for Epilepsy Services was appended to an England & Wales NHS Executive Letter EL(95)120 from the NHS Executive Director of Planning in January 19964. The effect of this executive letter has been studied5. Needs 1 therefore had an impact. Does it need revising? We feel it is appropriate to do so to take into account the changes in the structure of the NHS together with changes in the possibilities for treating epilepsy and developments in some specialist areas. This paper is mainly concerned with the situation in the UK, and seeks to identify needs which could and should be met through the National Health Service. Mention will also be made of the crucial importance of inter-agency liaison between health, social services and education. 
DEFINITION AND BORDERLANDS
An epileptic seizure is a brief, usually unprovoked, stereotyped disturbance of consciousness, behaviour, emotion, motor function or sensation which on clinical grounds results from cortical neuronal discharge. Seizures that occur during or after a known or suspected cerebral insult are referred to as acute symptomatic seizures. Where seizures occur in the absence of a presumed acute precipitating insult the term unprovoked seizures is used. These may be symptomatic or idiopathic/cryptogenic. Symptomatic unprovoked seizures are also called remote symptomatic seizures, and may occur in individuals who have welldemonstrated antecedent conditions known to be associated with seizures, such as cerebrovascular accident, penetrating head injuries, cerebral palsy or developmental abnormalities of the central nervous system.
Epilepsy is a condition characterized by recurrent unprovoked seizures. Many types of epileptic seizure are recognized, and the precise descriptions of seizure types together with other clinical data characterize specific epileptic syndromes. A syndrome diagnosis may give clues to aetiology and prognosis, and has implications for the choice of treatment.
Epilepsy is frequently overdiagnosed. In adults the most common cause of misdiagnosis is syncope, which may sometimes be a symptom of another, treatable, cardiac condition. Other conditions that may be mistaken for epilepsy include hysterical dissociative phenomena and panic disorder. In childhood, reflex anoxic and breath-holding attacks are often misdiagnosed. Misdiagnosis carries a dual penalty-unnecessary treatment for epilepsy together with a failure to treat the unrecognized actual disease. A quality epilepsy service will be able to address these issues and will be costeffective in terms of both health gain and economics.
EPIDEMIOLOGY
Incidence, prevalence and mortality rates Epilepsy is the most common serious neurological condition with a prevalence in the community about tenfold higher than that of multiple sclerosis and 100 times higher than that of motor neurone disease.
The annual incidence rate worldwide has been found usually to fall between 40-100 cases/ 100 000 persons. A recent UK study in a population of over two million persons, found an incidence rate of newly treated epilepsy of 80.8/100000 (95% confidence intervals (CI) 76.9-84.7) in 199S6. Age-specific incidence rates are highest in young children and in the elderly, and lowest in young adulthood and middle age. In the first year of life, the incidence of epilepsy is reported at between 70-220/100000. It falls to 50-150/100000 by 4 to 5 years, and stays at about 50-70/100 000 throughout the rest of childhood'.
The prevalence rate of epilepsy has usually been found to lie between 5-l O/l 000 persons, and is highest in old age. The UK overall prevalence rate of treated epilepsy is 5.15/1000 (95% CI 5.05-5.25). The prevalence rises from 2-7/1000 children at 2 years of age to 4-14/1000 by 15 years. The lifetime prevalence is between 2-5% of the population.
Mortality rates of individuals with epilepsy are between 2-4 times that of the age-matched population without epilepsy. The excess mortality is greatest amongst children and young adults and the standardized mortality rate is highest in the 10 years after diagnosis. Of particular concern is sudden unexpected death in epilepsy (SUDEP), which is probably usually due to central respiratory arrest during seizures, and which occurs at an annual rate of about l/100-200 persons with chronic active epilepsy*.
CLINICAL CHARACTERISTICS OF EPILEPSY IN THE POPULATION

Seizure types and syndromes
Approximately
60% of patients have tonic-clonic seizures (including 20% with secondarily generalized seizures), 20% complex partial seizures, 12% mixed tonic-clonic and partial seizures, about 3% simple partial seizures, and less than 5% absence seizures, myoclonic seizures and other seizure types.
About one-third of cases have less than one seizure a year, one-third have between one and 12 seizures per year, and the remainder more than one seizure per month (20% of these have more than one seizure per week).
Up to 60% of people with active epilepsy have additional neurological or neuropsychological handicaps, e.g. learning disabilities, behavioural disturbances, discrete cognitive impairment, focal neurological deficit.
Of patients seen by a paediatrician 15% will have severe epilepsy. West Syndrome, characterized by infantile spasms, accounts for at least 3% of childhood epilepsy, and the Lennox-Gastaut Syndrome (a condition in which refractory epilepsy occurs in the context of learning difficulties and cognitive deterioration in childhood) up to 6%. Childhood absence epilepsy occurs in 8%.
Thus in the general population, epilepsy occurs in a range of people from those who are otherwise normal to those with profound learning disability (mental handicap). One-third of people with learning disability have seizures.
In a population of 100 000 such as that served by a Primary Care Group in the UK, there will be about 80 new cases of epilepsy per year, and about 5 15 people under treatment for epilepsy. Of these, more than 170 will be having more than one seizure a month, and up to 300 may have additional handicaps. There will be one or two deaths per year from SUDEP.
Aetiology
Recent advances in Magnetic Resonance Imaging (MRI) have allowed the identification of aetiologies which were previously hidden. In populations of patients with chronic epilepsy, the underlying cause can now be determined in over two-thirds of cases. However, the frequency with which underlying causes can be uncovered in populations of newly diagnosed patients with the application of advanced MRI has not been fully established. Epilepsies in which no underlying cause can be found are best referred to as cryptogenic. With advances in imaging and genetic techniques, the proportion of cryptogenic cases is likely to diminish.
Of defined causes, the most common are cerebrovascular disease; cerebral tumours; genetic, congenital or hereditary conditions; alcohol, drugs and other toxic causes; head trauma (including post-neurosurgery); and post-infective causes (encephalitis and meningitis). Between lo-20% have idiopathic generalized epilepsy (IGE).
The potential for preventing epilepsy currently rests with improvements in the treatment of vascular disease and infections, and the avoidance of trauma, alcohol and other toxic causes. Improved pre-natal and peri-natal care might reduce the incidence of congenital causes of epilepsy, although in most cases, the nature of the pre-or peri-natal abnormality resulting in epilepsy is not fully understood. Much of the secondary handicap of epilepsy, however, whether physical, psychological or social, is eminently preventable by appropriate medical and social management.
COST AND BURDEN9
The annual medical costs of newly diagnosed epilepsy in the UK have been estimated to be in the region of fl8 million and the total annual costs of established epilepsy in the region off2 billion". Epilepsy has been estimated to account for about 0.2% of all UK general practice costs and 0.6% of all UK hospital costs. The pharmaceutical costs in the UK have risen by 220% in the past 5 years and now account for over f60 million annually. As the population demographics change, and the number of patients with epilepsy in the elderly age group rises, medical costs are likely to increase. It is also easy to underestimate the burden to parents of caring for a child with epilepsy.
In developing countries there is still a large 'treatment gap' in epilepsy, and studies have shown that, at any one time, between 80-95% of patients are not receiving drug therapy. This is largely due to a failure to provide adequate medical services. In the UK, too, at a rough approximation, 30% of patients with active epilepsy are not on therapy.
EVALUATING THE EVIDENCE
When guidelines are developed, recommendations are weighted by levels, based on the type of evidence that underwrites them". 'Level I' meta-analysis and randomized controlled trials provide the best information to recommend best practice. Unfortunately, there has been little research on this quality so far, apart from that on the effectiveness of antiepileptic drugs. As this document shows, although the research evidence is lacking, this does not mean that there are not considerable problems with the present level of care for patients with epilepsy. If progress is to be made, planning will have to be based on 'Level II, III, and IV' evidence from controlled studies, comparisons of care, and peer recommendations. There is a need for good quality research to demonstrate the most effective models for epilepsy ca.re12* 13.
MANAGEMENT OF INITIAL PRESENTATION
When a patient first has a seizure it usually presents to the general practitioner, whose task is to take a history from the patient and any eye witnesses, provide the patient with information, and make a referral to an epilepsy specialist. A general practitioner will only see one or two new cases of epilepsy a year. This is insufficient to develop skills in accurate diagnosis or initial treatment. Because of the potential problem of misdiagnosis it is important that patients are seen quickly after their first seizure by a consultant with an interest in epilepsy. General practitioners should not normally initiate treatment themselves unless the patient faces a long delay in seeing an epilepsy specialist. Then, the general practitioner could start antiepileptic drugs, preferably after discussion with the specialist. Use of local guidelines developed between primary and secondary care help to clarify responsibility in initial diagnosis and therapy. Relatively few districts have developed local guidelines and there is a need to evaluate their effectiveness.
Components of special initial assessment service
Ideally this should be an adult or paediatric neurological outpatient clinic. However, neurology remains a relatively scarce speciality, and many epilepsy services continue to be run by other physicians with a special interest in the condition, such as clinical pharmacologists or neuropsychiatrists who have developed skills in epileptology. The function of this hospital-led service will be to (a) make a diagnosis, (b) initiate treatment, (c) provide initial counselling and information to patients and their families, (d) monitor the response to the initial treatment and (e) refer the patient back to the general practitioner if the condition is stable. The service needs to have a capacity to see more people than actually have epilepsy. For every five people who have epilepsy the clinic will need to see at least two others who do not. Furthermore, it is appropriate for a seizure assessment service to have an ongoing commitment to patients in whom the diagnosis remains unclear, or who have non-epileptic seizures.
The forthcoming development of Primary Care Groups (PCGs) offers new opportunities. It may be possible for one general practitioner to develop further skills in managing epilepsy and work in close liaison with the district epilepsy services. This general practitioner would become the initial point of referral from his or her colleagues. PCGs will be responsible for developing 'clinical governance' for the patients they serve. There can be few chronic diseases better deserv-ing of consideration for improvement since repeated general practice audits over the last 30 years show that over 40% of affected people continue to have seizures, and many do not receive adequate care, information and advice about their epilepsy.
Investigations
Epilepsy is primarily a clinical diagnosis. The electroencephalogram (EEG) is an aid to determining the epilepsy syndrome and therefore assists in deciding on appropriate treatment. The routine EEG is not a diagnostic test for epilepsy. Every person with newly diagnosed epilepsy will require at least one standard EEG recording to assist with syndrome diagnosis, and up to 50% will require a second EEG.
Patients presenting with partial (focal) epilepsy should have neuroimaging investigations unless there is a clear, previously existing cause for epilepsy. This will apply to 50-60% of children presenting with epilepsy, and to at least the same proportion in the 16-65 age group. In new patients over the age of 65, the percentage requiring scanning may be lower because the aetiology may be clear already. MRI is superior to computerized tomography (CT) scanning in identifying lesions causing epilepsy, and is the preferred investigation. Identification of a structural lesion can have important treatment implications. Metabolic screening will be required as part of the diagnostic process in about 10% of children, especially those presenting with epilepsy in the first year of life.
Initial drug treatment
Currently the majority of patients will receive initial treatment with either sodium valproate or carbamazepine as monotherapy. There are potential problems with both of these drugs in women of childbearing age as they are both teratogenic. Lamotrigine has been licensed in monotherapy and may be used as initial treatment'", although, it is more expensive than valproate or carbamazepine. Some clinicians feel that it is too expensive to be used in monotherapy as a firstline drug but recent audited experience of its use in this role suggests that in monotherapy the effective dose is low so that its cost is not excessivei5. There is also evidence that gabapentin is effective in monotherapyt6, and this may be reflected in its licence in due course. The epileptic syndrome will influence the choice of drug, and it is important that care is taken over the initial diagnosis. Both valproate and lamotrigine have broad spectra of antiepileptic activity, while carbamazepine and gabapentin are most effective against partial-onset seizures. If used to treat primary generalized seizures, carbamazepine may make some types worse", while gabapentin is ineffectiveis.
In the early stages of treatment, patients whose epilepsy is refractory to these drugs or who are intolerant of them will be identified. In some of these cases, such as with localization-related epilepsy, phenytoin has been used as an alternative. However phenytoin is not recommended as a first-line antiepileptic drug due to its wide range of side effects. About one in 20 children with childhood absence epilepsy may show a better response to ethosuximide or to a combination of ethosuximide and valproate.
Where initial treatment does not control seizures, or where adverse reactions occur, there are a number of further medications and other treatment options which are referred to later in this paper.
There are compelling reasons for ensuring continuity of formulation in antiepileptic drug prescribing. It is therefore appropriate to prescribe by brand and it should be regarded as unsatisfactory to make sudden switches from branded to generic formulations'9.
CONTINUING CARE
After the initial treatment plan has been instituted, it should be expected that 60-70% of patients will become seizure free and will return to the primary care service for continuing care. The 30-40% of patients who continue to experience seizures will need further specialist follow-up; but, if their seizures prove intractable, they too may be returned to primary care. Some patients who choose not to attend specialist clinics or not to take medication will also remain in primary care.
The tasks involved in continuing care at a primary level are to monitor seizure frequency and drug sideeffects, alter medication when indicated, provide encouragement and support, and give information and counselling. Women with epilepsy need additional information and advice about contraception and pregnancy. Re-referral or access to specialist advice may be needed if seizures cannot be controlled; if cessation of treatment is possible, early in pregnancy, and for advice about lifestyle issues such as driving. Serum drug level monitoring in primary care is of little help except when there are doubts about adherence to prescribed medication. It is difficult to see how these tasks can be performed without a structured annual review. Whilst most patients discuss their epilepsy with their general practitioners at least once a year, this is not usually done in a formal way.
At present many general practitioners perceive a gap between the services that they currently provide for patients with epilepsy and the level of care they think that the patient should be receiving". Management of other chronic diseases such as diabetes and asthma is now routinely based in primary care. If primary care is to improve the level of care offered to patients with epilepsy then resources will need to be found. These extra resources could be used for district-based education, local guidelines, shared records, liaison through clinical nurse specialists, practice nurse run clinics, access to phone advice from the specialist and information sources, audit at practice and district levels, and a chronic management data set. All these ideas are already being used by enthusiastic practices to improve the present level of service".
In secondary care the tasks of continuing care are to investigate intractable seizures, alter medication, assess for neurosurgery, advise on stopping treatment, manage epilepsy in pregnancy, and to inform and educate patients. Liaison with primary care and patient organizations is most effective when there is a team-based approach using specialist nurses.
Epilepsy plus
The 30%-40% of patients who continue to require access to specialist epilepsy services will do so because of one or more of the following problems: Into this group of 'epilepsy plus' would also fall those referred back to the specialist service after initial assessment and treatment but who have developed additional epilepsy-related problems, or a deterioration in seizure control, although this last group should be numerically small. Nevertheless we would recommend that anyone who is still having seizures 2 years after diagnosis should be re-referred. At re-referral, critical assessment of the original diagnosis should be made and further appropriate investigations performed. If the diagnosis of epilepsy is no longer certain, special EEG studies to record a seizure should be undertaken if possible (using ambulatory EEG monitoring with video records or telemetered EEG/video recording). A high quality MRI scan should be considered mandatory in all patients who continue to have seizures after 2 years.
The range of possible therapies for the 'epilepsy plus' group includes exposure to second-line drugs, exposure to experimental drugs, epilepsy surgery, further assessment in a special assessment unit, alternative treatment options and neuropsychiatric follow-up. Other issues 439 that may have to be addressed are special educational referral, arrangements for care in the community and long-term care.
New trends in antiepileptic drug treatment
In the last 10 years several new antiepileptic drugs have come onto the market: vigabatrin, lamotrigine, gabapentin, topiramate and, most recently, tiagabine. All have been shown in double-blind controlled trials to be more effective than a placebo in controlling partial-onset seizures (with or without secondary generalization). Meta-analysis of these trials suggests that none of them is more effective than any other although vigabatrin and topiramate had significantly more side effects than their corresponding placebo". It should be remembered, however, that a clinical trial merely demonstrates that there has been a significant reduction in the patients' seizures-not abolition of them-once on the market, a great deal of experience is needed with the drug before its place in the therapeutic armentarium is established.
Lamotrigine is a broad-spectrum antiepileptic drug, which is now licensed for monotherapy and may be used in newly diagnosed epilepsy. (It was discussed earlier in the section on initial treatment.) It has also been shown to be effective in Lennox-Gastaut Syndrome, a difficult-to-treat epileptic syndrome of childhood, which is relatively common in the population with learning disability'". Of the other drugs, it is suggested that vigabatrin is restricted to specialist use (particularly until its role in causing peripheral visual loss has been fully determined). Some would also consider that topiramate is also restricted to specialist use because of its side-effect profile: Tiagabine is too new to recommend anything but specialist use, and its potential to cause visual field loss requires further evaluation. Gabapentin is also as effective as standard drugs in new onset seizures but its role as a monotherapy drug is as yet less clearly defined.
Experimental drugs
Patients attending specialist epilepsy clinics may have access to potential antiepileptic drugs undergoing phase 2 and 3 trials, or may have access to these agents on a named patient compassionate use basis in some circumstances, with appropriate ethical committee approval and informed consent.
Epilepsy surgery S. Brown et al.
Other treatment options Surgery should be considered fairly early in young people with uncomplicated partial epilepsy originating in the temporal lobes and not responding to first-line treatment with drugs. The results of surgery are good in patients who have been appropriately investigated and identified as suitable candidates.
Pre-surgical evaluation requires an experienced team. The team will include specialists in neuroradiology, neurophysiology, neuropsychiatry and neuropsychology as well as in epilepsy and neurosurgery. Access to high quality MRI with the facility for volumetric measurement of the hippocampi and other imaging techniques is essential, as is access to detailed neurophysiology including intracranial recordings. On epidemiological grounds, 30 people per million of the population per year could be evaluated for epilepsy surgery and of these approximately one-third (10 per million) would go forward for operation. Of those operated upon 70-85% would have a very satisfactory outcome (completely seizure free or only very occasional seizures). Thus a health region with a population of four million should be evaluating 120 people per year and operating on 40 of these.
Besides resective surgery for partial epilepsy, the same team would be involved in alternative approaches such as callosotomy and hemispherectomy for specific situations and vagal nerve simulation for intractable epilepsy unsuitable for resective surgery.
It is essential to recognize that suitability for surgery depends on ictal EEG and specific MRI criteria, not on the result of a random EEG. If curative surgery is done too late in the patient's epileptic career, rehabilitation will be difficult.
Special assessment units
For patients with 'epilepsy plus' where problems in diagnosis and treatment cannot be resolved with outpatient resources or short-term inpatient admission to a neurology service, a more prolonged admission to a special epilepsy assessment unit can be beneficial. In such units the diagnosis can be reassessed, seizures intensively monitored and the relationship between epilepsy and behaviour evaluated and degrees of social handicap, learning difficulties and educational problems assessed. Specialized treatment of neuropsychiatric complications can be carried out and recommendations made for the most suitable treatment and follow-up in medical, psychological and social spheres. An assessment admission may last between 6 and 12 weeks. Approximately 5% of all people with epilepsy would benefit from such an admission at some time.
Some refractory epilepsies may respond to behavioural psychotherapy. This needs to be carried out by a psychiatrist, clinical psychologist or nurse therapist with appropriate training. A typical course of treatment takes up to 12 one-hour sessions spread over several months. A few patients require more, and others, fewer sessions. Some children and a smaller number of adults with refractory epilepsy respond to a ketogenic diet, such as the medium chain triglyceride diet. Specialised epilepsy services should have the resources to identify potential responders and initiate and monitor treatment.
Other non-pharmacological treatments are currently under evaluation and may be part of a specialized epilepsy service. These may include elements of complementary medicine as well as more orthodox approaches.
Neuropsychiatric follow-up
Psychiatric morbidity in epilepsy is in excess of that of the general population, being present in approximately 50% of the 'epilepsy plus' group (or 1800 per million of the population in the community) and in up to 30% of all identified patients with epilepsy. The excess morbidity includes:
(a) that caused by the neurological condition that also causes the epilepsy; Aetiological factors, other than brain disease or malformation associated with the epilepsy, range from drug side effects to the psychosocial consequences of acquiring the diagnosis of epilepsy.
Recognition and management of these particular conditions are not a significant part of the routine training of neurologists, psychiatrists or general practitioners. Because of the interaction between the neurological and psychiatric components and the special treatment issues involved, any specialized epilepsy service must include a neuropsychiatric input.
Epilepsy needs revisited A note on non-epileptic seizures (NES)
Between lO-20% of patients referred to a specialist epilepsy service have seizures that are not epileptic. These phenomena are referred to as 'non-epileptic seizures' (NES) or 'non-epileptic attack disorder' (NEAD). In Britain a significant number of cases of 'status epilepticus' admitted to hospital are actually 'pseudo-status epilepticus' and the patient may suffer iatrogenic damage from overzealous treatment. Patients with NEAD referred to specialist units typically have a history of frequent hospital admissions with a background of social problems and so inappropriately consume considerable health service resources. However, the outcome of treatment of non-epileptic seizures in specialist units is good, with fewer hospital admissions at follow-up and improvement in social functioning.
Components of the teams needed to address these issues
The team involved in initial diagnosis and stabilization should include the following: intensive EEG facilities including ambulatory monitoring, telemetry and intracranial recordings with video monitoring; a neuroradiologist familiar with the detection of mesial temporal sclerosis in MR scans and with hippocampal volumetric analysis; nursing staff especially attached to the service and trained in epilepsy (clinical nurse specialist or epilepsy nurse practitioner); a special service for adolescents with epilepsy (aged 12-18) with appropriate nursing input; a special service for women with epilepsy (e.g. pre-conception counselling, pregnancy liaison, menopause advice) with epilepsy nursing input; team members (nursing, medical) familiar with the needs of people with learning disability; access to dedicated social work services and occupational therapists; Summaries of epidemiological data and service needs per 100 000 population are given in Appendix 1.
SPECIAL ISSUES Pregnancy and women's issues21g22
Pre-conceptual courtselling Pre-conceptual advice about the teratogenicity of antiepileptic drugs needs to be given at an early age so that specialist help is sought when patients are contemplating a pregnancy. At diagnosis, adolescent girls and women of childbearing age should be given information about contraception and pregnancy. They should be told that if they wish to become pregnant, they need to seek pre-pregnancy counselling and referred to a specialist with an interest in the subject. High dose of folate supplements (5 mg/day) should be started before contraception is discontinued. This advice should be given routinely at the time of an annual epilepsy review or during a consultation for contraception. Pre-pregnancy counselling issues include the continuing need for treatment during pregnancy, the most suitable medication during pregnancy, and the risk of foetal malformations and foetal anticonvulsant syndrome. Many women are also worried about the genetics of their seizure disorder.
Contraception
Any possible interactions between the antiepileptic drug and the combined oral contraceptive pillZ need to be discussed. It should be stressed that non-hormonal methods of contraception are not affected by epilepsy.
Fertility
The fertility rate of women with epilepsy in the UK has been found to be 47.1 (95% CI 42.3-52.4) live births/l000 women per year, which is significantly lower than that of the general population. Women of childbearing age who have epilepsy need to be warned that their fertility might be affected by epilepsy and possibly by antiepileptic drugs. There have been recent reports of an association of sodium valproate therapy with endocrine changes and the polycystic ovary syndrome26. If a woman has problems conceiving, she needs to seek specialist help.
Pregnancy
Once a woman with epilepsy is pregnant, there needs to be close liaison between the specialist managing the seizure disorder and the obstetrician. These are highrisk pregnancies with increased incidence of complications and adverse outcomes of pregnancy as well as possible alterations in seizure frequency. Once a child is born, breast-feeding should be encouraged. Safety in the home and problems of looking after a child need to be discussed. If pre-pregnancy counselling did not occur and further children are wanted, the woman needs to be referred to discuss her antiepileptic therapy.
Menopause
There is very little data relating to epilepsy and the menopause, in particular hormone replacement therapy. As many women who have been on therapy for epilepsy are at a high risk of developing osteoporosis and fractures, a trial of hormone replacement therapy (HRT) should be given. It is suggested that a progestogen should always be used with oestrogen in HRT in women with epilepsy, even when the uterus is no longer present25.
dren, especially where there may be an incomplete history when the person lives alone. Seizures may pose a special risk for the elderly, and their onset may be a turning point when self-confidence and functional independence are lost. Unless the onset of seizures is associated with the terminal phase of an illness, patients should be referred to a specialist for accurate diagnosis and advice about treatment. Secondary prevention of strokes is a promising area of development and symptoms caused by a primary or secondary cerebral tumour can often be eliminated or ameliorated.
Special issues in children
At least 25% of children with epilepsy will have some form of special educational needs. At least 20% have moderate or severe learning difficulties. The difficulties of children who have specific learning difficulties, for example, specific reading and writing or specific arithmetical problems in association with epilepsy, are often under estimated. There is ample evidence that seizure discharges interfere with cognitive abilities27. There is often an assumption on the part of teachers and other non-medical personnel that antiepileptic drugs will dull intellectual abilities. Controlled studies of the possible cognitive effects of antiepileptic drugs have suggested that these are not the main factors responsible for school difficulties, but that the underlying pathology, of which epilepsy is the symptom, is crucial.
It is important that the difficulties experienced by children with epilepsy at school are clearly identified and addressed. Liaison between consultant-led paediatric services, education authorities and school staff is often less than idea128, yet, good practice today will have beneficial consequences for tomorrow's adults and implications for long-term service provision. Community paediatricians should be aware of special educational resources for children with epilepsy. When the medical contribution to an educational needs assessment is being written, this should contain relevant information about seizure type, syndrome and aetiology, together with an account of the effect the epilepsy and its treatment are having in the classroom. This will require liaison between the community paediatrician, the epilepsy team and health visitor and community nurse services.
Epilepsy in older people
Epilepsy in adults with learning disability The incidence of epilepsy is bi-modal, and increases in older age groups when partial seizures become more common. Cerebral atherosclerosis and tumours are the main causes. Ten percent of patients suffering a stroke have seizures within 5 years. Epilepsy may present differently in older people than in young adults and chil-'Learning disability' (LD) is the term used in the UK to refer to what is elsewhere called 'mental retardation'. Epilepsy is common in this population, the likelihood increasing with severity of LD and presence of associated conditions2g-31. About 30% of patients who are in touch with LD services have a diagnosis of epilepsy and this may approach 50% in institutional populations. Even in those with mild learning disability the prevalence rate is about 6%, ten times greater than in the general population32T33. Furthermore, there are epilepsy syndromes that tend to be associated with LD and in which the seizures can be difficult to treat, such as Lennox-Gastaut syndrome. Disability awareness is currently not a part of routine neurology training. LD teams that are properly resourced play a crucial part in the management of epilepsy in this group of patients, and medical staff specializing in LD may acquire the necessary skills. Epilepsy tends to be more refractory in this group, and patients need ongoing contact with specialist services. People with LD and those without should have equity of access to quality services3'. Recognizing this still requires a culture shift among some staff working in radiology and neurophysiology departments, local standards could be set to ensure that an expected level of service is achieved.
Status epilepticus
Status epilepticus is defined as a condition in which epileptic activity persists for 30 minutes or more. This can result in a wide spectrum of clinical symptoms and have a highly variable pathophysiological, anatomical and aetiological basis. One calculation of the frequency of status epilepticus in the general population suggests that there are over 50 cases/l00000 persons per year (approximately 30 000 cases in the UK each year), but other estimates are much higher. The condition is common in children. Over 50% of cases occur due to an acute cerebral event in patients without a prior history of epilepsy. In patients with established epilepsy, the frequency of status is highest in those with chronic or severe epilepsy, additional handicaps, learning disability or structural cerebral damage (particularly in the frontal lobe). The differentiation of pseudo-status epilepticus (a psychologically determined condition) can pose problems and due attention should be taken to the previous medical history. Most forms of status epilepticus are emergencies, requiring admission to hospital and emergency therapy. Tonic-clonic status epilepticus (convulsive status epilepticus) is the most typical form, and canies a mortality rate of about 20% and a higher rate of neurological morbidity. Much of the morbidity and mortality is due to the underlying cause of the status, but is exacerbated by inappropriate or inadequate treatment'". All casualty and neurological departments should have a treatment protocol, such as that shown in Appendix 2. The treatment of convulsive status is staged into therapy for early status, established and refractory status. Refractory convulsive status epilepticus requires admission to an Intensive Care Unit, with access to EEG monitoring. Nonconvulsive forms of status do not usually require emergency therapy367 37.
Long-term care
Approximately 700 people per million of the population may require long-term care because of epilepsy and associated problems. This is most commonly due to refractory epilepsy in association with learning disability, though associated psychiatric illness or any combination of these factors may be relevant. Responsibility for placement frequently lies with local authority social services, but the additional health-related costs should be borne by health authorities of origin, and budgetary allowance should therefore be made for this. It is unacceptable that access to services should be denied or delayed because of the failure of social services departments and health authorities to come to joint arrangements about funding. This has happened all too often in the past. The current government policy to encourage joint commissioning of services may help to make the service more seamless to the user. Where such arrangements are in place it is important that commissioning agencies specify the health component properly fo! people with epilepsy.
RESOURCE IMPLICATIONS
The consistent delivery of high-quality cost-effective services to people will mean improving the training of doctors and nurses and other health professionals and the education of managers and purchasers. Neurophysiology and scanning facilities will need to be expanded and made 'user friendly' for the large number of leaming disabled patients that will need to use them.
Undergraduate medical education in epilepsy will need to be enhanced (as will nurse education) and clinicians encouraged to use epilepsy in special study modules in the new undergraduate curriculum (as already happens in the University of Birmingham). Senior and junior trainees in hospital practice (particularly in neurophysiology, neurology, psychiatry and learning disability) will need to spend time in quality epilepsy units and clinics. Doctors training in primary care should be exposed to epilepsy experience (auditing their practices in epilepsy care is a useful exercise).
Community paediatricians need better training in the complex needs of the child with epilepsy (particularly those with learning difficulties or physical handicap). Practice nurse training (particularly to set up miniclinics in primary care) is essential and models already exist as to how this should be done38. There has been an expansion of specialist nurses in epilepsy who need appropriate high level training: the development of high quality distance learning university courses such as that offered by Leeds Metropolitan University is to be commended.
The voluntary organizations for people with epilepsy have an important role in general education, in reducing stigma and in educating people with epilepsy to demand better services-'patient power' can become a reality. 
